Skip to content
Search

Latest Stories

Community pharmacy witnesses highest dispensing activity in 2021/22, report reveals

Dispensing activity by community pharmacy in England has witnessed a 4.2 per cent increase across the year 2021 till March 2022, the Pharmacy Market Review 2022 report revealed.

The report launched by Christie & Co, said: “All pharmacy settings saw improvements in dispensing numbers, with standard community settings seeing the highest increase of 4.2 per cent, with the average moving to 7,173 items, albeit still below the combined average.”


“The independent sector fared better than corporate pharmacy, with a combined average increase of 3.5 per cent versus a 1.8 per cent increase in corporate dispensing. Despite some improvement, integrated pharmacies remained the lowest at 1.9 per cent, in part due to the continued restrictions on patient access.”

Dispensing activity for England across the year to March 2022 increased by 4.5 per cent to an average of 7,765 items per month, reversing the decline witnessed in 2021.

Resourcing Challenges

Analyzing both valuation and transactional data for 2021/22, Christie & Co found that wages (including locum costs) have risen by 0.2 per cent, wages (excluding locum costs) have risen by 0.5 per cent, locum costs as a percentage of total wage costs have fallen by 2.9 per cent, the EBITDA margin has risen by 1.7 per cent, and Gross Profit margin has risen by 1.9 per cent.

"Resourcing in the sector remains challenging and has placed a huge strain on community pharmacies, as, increasingly, staff are being lured away."

According to data supplied by Locate a Locum to Christie & Co, the average hourly rate as of July 2022 for locum cover across the UK was £37.49, an increase of £4.81 on the 12-month average it recorded in 2021. In England, hourly locum rates increased to circa £36.95, whereas in Wales and Scotland the rates increased to £37.93 and £48.86, respectively.

Online pharmacy platforms

Throughout the UK’s lockdowns, remote dispensing via online platforms, and the benefits that it brought both operators and patients, was invaluable, and dispensing numbers rose as a result. Of a group of seven operators sampled by Christie & Co, all but one showed continued online dispensing item growth, returning a combined average increase of 22 per cent in the 12 months to June 2022.

Total items dispensed by key online pharmacy platform increased by 202 per cent from 2020 to 2021, from 12.1 million to 24.5 million. There was a further 22 per cent increase from 2021 to 2022, taking the total to 29.9 million.

Funding 

Christie Finance highlighted rising pressure from lenders for borrowers to evidence that there is enough ‘proven’ profit to cover any finance loans once they have withdrawn what they need for themselves.

"With a few key funders withdrawing from the pharmacy finance market in 2022, existing lenders are needed to fill this void. With ‘alternative’ and sometimes less experienced lenders, it has been harder for buyers to access the finance they require."

However, there is no shortage of demand for pharmacies. Year to date, Christie Finance has witnessed a 35 per cent increase in instructions, with keen buyers seeking support and guidance.

Tony Evans, Head of Pharmacy at Christie & Co, comments, “As we have emerged from the grips of the pandemic, the sector has continued to deliver its pivotal primary care role. Whilst there have been gains in dispensing volumes, the sector has also had to contend with increasing cost headwinds exemplified in supply and drug pricing issues, as well as staff resourcing issues alongside significant increases in locum costs.

“Nonetheless over the last year, we have witnessed many pharmacy contractors keen to expand their businesses both through acquisition as well as the development of additional services. As a result, the market has continued to see positive activity, something we reported in our Business Outlook 2022 publication. We are pleased to report that this trajectory has continued, mirroring that of the previous year, with appetite across all aspects of the market.”

The report analyzed key trends in the pharmacy sector in 2021 and the first half of 2022; reviewing market composition, operational activity, employment challenges, key dispensing and services activity, online pharmacy platforms, and sector funding. It also includes publicly available data and proprietary data from key business intermediaries, including Locate a Locum.

Christie & Co reported positive market activity, with prices bouncing back from an almost static level in 2020 to a 4.3 per cent increase in 2021, a trajectory that has continued in 2022 across all market areas.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less